Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Allam was serving recently as the CEO at Public Investment Fund
The camps were organised along with the doctors from Bharti Vidyapeeth Dental College and Hospital, Katraj, Pune, and Emcure’s occupational health centre (OHC) doctors
None of the observations are related to data integrity and management believes that they are addressable
Positive opinions based on significant survival benefit
This digital linking of individual’s health records with ABHA is being carried out extensively across different health facilities of the country
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
Subscribe To Our Newsletter & Stay Updated